MXPA05009722A - Inhibidores heterociclicos de cinasa: metodos de uso y sintesis. - Google Patents
Inhibidores heterociclicos de cinasa: metodos de uso y sintesis.Info
- Publication number
- MXPA05009722A MXPA05009722A MXPA05009722A MXPA05009722A MXPA05009722A MX PA05009722 A MXPA05009722 A MX PA05009722A MX PA05009722 A MXPA05009722 A MX PA05009722A MX PA05009722 A MXPA05009722 A MX PA05009722A MX PA05009722 A MXPA05009722 A MX PA05009722A
- Authority
- MX
- Mexico
- Prior art keywords
- alkyl
- independently
- heterocyclyl
- heteroaryl
- halogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45345703P | 2003-03-10 | 2003-03-10 | |
US46091003P | 2003-04-07 | 2003-04-07 | |
US46302503P | 2003-04-15 | 2003-04-15 | |
US50271003P | 2003-09-12 | 2003-09-12 | |
PCT/US2004/007286 WO2004080463A1 (en) | 2003-03-10 | 2004-03-10 | Heterocyclic kinase inhibitors: methods of use and synthesis |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05009722A true MXPA05009722A (es) | 2006-03-09 |
Family
ID=32996376
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05009722A MXPA05009722A (es) | 2003-03-10 | 2004-03-10 | Inhibidores heterociclicos de cinasa: metodos de uso y sintesis. |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1601357A4 (ja) |
JP (1) | JP2006519846A (ja) |
CA (1) | CA2518398A1 (ja) |
MX (1) | MXPA05009722A (ja) |
WO (1) | WO2004080463A1 (ja) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
MX2008002363A (es) | 2005-08-17 | 2008-03-18 | Schering Corp | Ligandos novedosos de cinasa basados en quinolina de alta afinidad. |
DK3421471T3 (da) | 2006-04-25 | 2021-06-14 | Astex Therapeutics Ltd | Purin- og deazapurinderivater som farmaceutiske forbindelser |
US7511063B2 (en) * | 2006-08-16 | 2009-03-31 | Schering Corporation | High affinity quinoline-based kinase ligands |
US7964732B2 (en) | 2006-11-17 | 2011-06-21 | Pfizer Inc. | Substituted bicyclocarboxyamide compounds |
CA2669590A1 (en) | 2006-12-07 | 2008-06-12 | F. Hoffmann-La Roche Ag | 2-aminoquinolines as 5-ht(5a) receptor antagonists |
MX2009009793A (es) | 2007-03-14 | 2009-10-16 | Ranbaxy Lab Ltd | Derivados de pirazolo (3,4-b) piridina como inhibidores de fosfodiesterasa. |
PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
CA2687230A1 (en) * | 2007-05-23 | 2008-12-11 | Merck & Co., Inc. | Cyclopropyl pyrrolidine orexin receptor antagonists |
JP2010536872A (ja) * | 2007-08-22 | 2010-12-02 | アラーガン、インコーポレイテッド | 治療用キノリンおよびナフタレン誘導体 |
MX2010003001A (es) * | 2007-09-27 | 2010-04-01 | Hoffmann La Roche | Derivados de quinolina como antagonistas del receptor de la 5-hidroxitriptamina 5a. |
AU2008309383B2 (en) | 2007-10-11 | 2012-04-19 | Astrazeneca Ab | Pyrrolo [2, 3 -D] pyrimidin derivatives as protein kinase B inhibitors |
EP2202228B1 (en) | 2007-10-15 | 2014-12-10 | Takeda Pharmaceutical Company Limited | Amide compounds and use of the same |
ES2389992T3 (es) | 2007-11-02 | 2012-11-05 | Vertex Pharmaceuticals Incorporated | Derivados de [1H-pirazolo[3,4-b]piridin-4-il]-fenilo o -piridin-2-ilo como proteína cinasa c-theta |
WO2009095752A1 (en) * | 2008-01-29 | 2009-08-06 | Glenmark Pharmaceuticals, S.A. | Fused pyrazole derivatives as cannabinoid receptor modulators |
WO2009109477A1 (en) * | 2008-03-05 | 2009-09-11 | F. Hoffmann-La Roche Ag | 2-aminoquinolines |
BRPI0910253A2 (pt) | 2008-03-07 | 2015-09-29 | Hoffmann La Roche | derivados de 2-aminoquinolina |
AU2009221294A1 (en) * | 2008-03-07 | 2009-09-11 | F. Hoffmann-La Roche Ag | 2-Aminoquinolines |
EP2254666A1 (en) | 2008-03-12 | 2010-12-01 | F. Hoffmann-La Roche AG | 2-aminoquinolines as 5-ht5a receptor antagonists |
GB0812969D0 (en) | 2008-07-15 | 2008-08-20 | Sentinel Oncology Ltd | Pharmaceutical compounds |
CN105837560A (zh) | 2009-02-27 | 2016-08-10 | 埃姆比特生物科学公司 | 调控jak激酶的喹唑啉衍生物和其使用方法 |
AU2010221417A1 (en) * | 2009-03-02 | 2011-09-22 | Sirtris Pharmaceuticals, Inc. | 8-substituted quinolines and related analogs as sirtuin modulators |
WO2010143169A2 (en) * | 2009-06-12 | 2010-12-16 | Société Splicos | Compounds useful for treating aids |
US10253020B2 (en) | 2009-06-12 | 2019-04-09 | Abivax | Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging |
GEP201606506B (en) * | 2009-12-17 | 2016-07-11 | Merck Sharp & Dohme | Quinoline amide m1 receptor positive allosteric modulators |
NZ600857A (en) | 2010-01-29 | 2014-06-27 | Boehringer Ingelheim Int | Substituted naphthyridines and their use as syk kinase inhibitors |
US8815902B2 (en) | 2010-06-15 | 2014-08-26 | Merck Sharp & Dohme Corp. | Tetrahydroquinoline amide M1 receptor positive allosteric modulators |
MX2013000748A (es) * | 2010-08-27 | 2013-03-05 | Gruenenthal Gmbh | 2-amino-quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3. |
MX2013002384A (es) | 2010-09-01 | 2013-07-05 | Ambit Biosciences Corp | Compuestos quinazolina y metodos para utilizarlos. |
EP2489663A1 (en) | 2011-02-16 | 2012-08-22 | Almirall, S.A. | Compounds as syk kinase inhibitors |
US9051305B2 (en) | 2011-03-08 | 2015-06-09 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
SG193505A1 (en) | 2011-04-01 | 2013-10-30 | Astrazeneca Ab | Therapeutic treatment |
WO2012154520A1 (en) | 2011-05-10 | 2012-11-15 | Merck Sharp & Dohme Corp. | Pyridyl aminopyridines as syk inhibitors |
US9145391B2 (en) | 2011-05-10 | 2015-09-29 | Merck Sharp & Dohme Corp. | Bipyridylaminopyridines as Syk inhibitors |
KR20140028062A (ko) | 2011-05-10 | 2014-03-07 | 머크 샤프 앤드 돔 코포레이션 | Syk 억제제로서의 아미노피리미딘 |
MX336224B (es) | 2011-07-26 | 2016-01-12 | Boehringer Ingelheim Int | Quinolinas sustituidas y su uso como medicamentos. |
US9006444B2 (en) | 2011-10-05 | 2015-04-14 | Merck Sharp & Dohme Corp. | Phenyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors |
EP2763976B1 (en) | 2011-10-05 | 2016-05-18 | Merck Sharp & Dohme Corp. | 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
US8987456B2 (en) | 2011-10-05 | 2015-03-24 | Merck Sharp & Dohme Corp. | 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors |
AU2012321110B2 (en) | 2011-11-30 | 2014-10-23 | Astrazeneca Ab | Combination treatment |
AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
WO2013192125A1 (en) | 2012-06-20 | 2013-12-27 | Merck Sharp & Dohme Corp. | Pyrazolyl derivatives as syk inhibitors |
US20150133450A1 (en) | 2012-06-20 | 2015-05-14 | Eutropics Pharmaceuticals, Inc. | Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives |
EP2863913B1 (en) | 2012-06-20 | 2018-09-12 | Merck Sharp & Dohme Corp. | Imidazolyl analogs as syk inhibitors |
WO2013192088A1 (en) | 2012-06-22 | 2013-12-27 | Merck Sharp & Dohme Corp. | SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
EP2863916B1 (en) | 2012-06-22 | 2018-07-18 | Merck Sharp & Dohme Corp. | Substituted pyridine spleen tyrosine kinase (syk) inhibitors |
EP2884982B1 (en) | 2012-08-20 | 2017-09-20 | Merck Sharp & Dohme Corp. | SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
US9586931B2 (en) | 2012-09-28 | 2017-03-07 | Merck Sharp & Dohme Corp. | Triazolyl derivatives as Syk inhibitors |
WO2014081953A1 (en) | 2012-11-21 | 2014-05-30 | Richard David J | Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives |
EP2757161A1 (en) | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
WO2015017788A1 (en) | 2013-08-01 | 2015-02-05 | Eutropics Pharmaceuticals, Inc. | Method for predicting cancer sensitivity |
WO2015066305A1 (en) | 2013-10-30 | 2015-05-07 | Eutropics Pharmaceuticals, Inc. | Methods for determining chemosensitivity and chemotoxicity |
EP3083559B1 (en) | 2013-12-20 | 2021-03-10 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
US9783531B2 (en) | 2013-12-20 | 2017-10-10 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
US9670196B2 (en) | 2013-12-20 | 2017-06-06 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as Spleen Tyrosine Kinase inhibitors |
EP3116506B1 (en) | 2014-03-13 | 2019-04-17 | Merck Sharp & Dohme Corp. | 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors |
EP2974729A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
AU2015338844B2 (en) * | 2014-10-31 | 2019-09-19 | Genoscience Pharma | Substituted 2,4 diamino-quinoline as new anticancer agents |
JP6969800B2 (ja) * | 2016-05-04 | 2021-11-24 | ジェノシアンス ファルマ | 増殖性疾患の治療に使用される置換2,4−ジアミノ−キノリン誘導体 |
CN110678461B (zh) * | 2017-06-14 | 2021-08-10 | 正大天晴药业集团股份有限公司 | Syk抑制剂及其使用方法 |
US11028068B2 (en) | 2017-07-25 | 2021-06-08 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
EP3620164A1 (en) * | 2018-09-05 | 2020-03-11 | Genoscience Pharma SAS | Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins b (ctsb), l (ctsl) and d (ctsd) related diseases |
US20220017498A1 (en) | 2018-12-14 | 2022-01-20 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Salt of syk inhibitor and crystalline form thereof |
EP3669873A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use ine the traeatment of inflammation diseases |
WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
TW202216713A (zh) | 2020-07-02 | 2022-05-01 | 美商英塞特公司 | 作為jak2 v617f抑制劑之三環脲化合物 |
WO2022006456A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic pyridone compounds as jak2 v617f inhibitors |
WO2022046989A1 (en) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
US11958861B2 (en) | 2021-02-25 | 2024-04-16 | Incyte Corporation | Spirocyclic lactams as JAK2 V617F inhibitors |
WO2023099589A1 (en) * | 2021-12-01 | 2023-06-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Irap inhibitors for use in the treatment of inflammatory diseases |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2472066A (en) * | 1949-06-07 | Z-arylamino-x-halogenoqtjinolines | ||
DE537104C (de) * | 1926-05-04 | 1933-03-17 | Chem Ind Basel | Verfahren zur Darstellung von substituierten Chinolincarbonsaeureamiden |
DE858698C (de) * | 1951-02-09 | 1952-12-08 | Basf Ag | Verfahren zur Herstellung von Pyridin- und Chinolinderivaten |
GB811957A (en) * | 1956-03-01 | 1959-04-15 | Geigy Ag J R | Improvements relating to 2-hydroxy-4-arylamino-quinolines |
FR6103M (ja) * | 1967-02-22 | 1968-06-10 | ||
US3755332A (en) * | 1971-07-01 | 1973-08-28 | Ciba Geigy Corp | Substituted 4 indazolaminoquinolines |
FR2538388B1 (fr) * | 1982-12-24 | 1985-06-21 | Pharmuka Lab | Nouveaux derives de naphtalene- ou azanaphtalenecarboxamide, leurs procedes de preparation et leur utilisation comme medicaments |
JPH05310702A (ja) * | 1992-05-06 | 1993-11-22 | Kyowa Hakko Kogyo Co Ltd | 抗炎症剤、免疫調整剤およびキノリン−2,4−ジカルボン酸ジアミド誘導体 |
GB9622363D0 (en) * | 1996-10-28 | 1997-01-08 | Celltech Therapeutics Ltd | Chemical compounds |
AU1251499A (en) * | 1997-11-26 | 1999-06-15 | Cerebrus Limited | (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders |
US6303593B1 (en) * | 1999-03-02 | 2001-10-16 | Merck & Co., Inc. | 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity |
US6479504B1 (en) * | 1999-06-16 | 2002-11-12 | The University Of Iowa Research Foundation | Antagonism of immunostimulatory CpG-oligonucleotides by 4-aminoquinolines and other weak bases |
US6593324B2 (en) * | 2000-03-01 | 2003-07-15 | Orion Corporation | Dervatives of quinoline as alpha-2 antagonists |
WO2002014269A2 (en) * | 2000-08-16 | 2002-02-21 | Neurogen Corporation | 2,4-substituted pyridine derivatives |
US6900226B2 (en) * | 2000-09-06 | 2005-05-31 | Hoffman-La Roche Inc. | Neuropeptide Y antagonists |
KR100621287B1 (ko) * | 2001-05-21 | 2006-09-13 | 에프. 호프만-라 로슈 아게 | 신경 펩타이드 y 수용체에 대한 리간드로서의 퀴놀린유도체 |
GB0118479D0 (en) * | 2001-07-28 | 2001-09-19 | Astrazeneca Ab | Novel compounds |
SE0102858D0 (sv) * | 2001-08-27 | 2001-08-27 | Astrazeneca Ab | N-type calcium channel antagonists for the treatment of pain |
GB0206215D0 (en) * | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
CA2489560A1 (en) * | 2002-06-27 | 2004-01-08 | Schering Aktiengesellschaft | Substituted quinoline ccr5 receptor antagonists |
MXPA05009723A (es) * | 2003-03-10 | 2006-02-17 | Schering Corp | Analisis de ligando. |
-
2004
- 2004-03-10 JP JP2006507031A patent/JP2006519846A/ja active Pending
- 2004-03-10 MX MXPA05009722A patent/MXPA05009722A/es not_active Application Discontinuation
- 2004-03-10 CA CA002518398A patent/CA2518398A1/en not_active Abandoned
- 2004-03-10 EP EP04719237A patent/EP1601357A4/en not_active Withdrawn
- 2004-03-10 WO PCT/US2004/007286 patent/WO2004080463A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2004080463A1 (en) | 2004-09-23 |
EP1601357A4 (en) | 2007-10-03 |
EP1601357A1 (en) | 2005-12-07 |
CA2518398A1 (en) | 2004-09-23 |
JP2006519846A (ja) | 2006-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA05009722A (es) | Inhibidores heterociclicos de cinasa: metodos de uso y sintesis. | |
JP2006519846A5 (ja) | ||
US8242271B2 (en) | Heterocyclic compounds and uses thereof | |
JP4173738B2 (ja) | Erk2の複素環式インヒビターおよびその使用 | |
EP1592686B1 (en) | Gyrase inhibitors and uses thereof | |
JP6054406B2 (ja) | Fgfrキナーゼ阻害を介した抗癌ベンゾピラジン | |
US20090042928A1 (en) | Modulators of muscarinic receptors | |
JP2012525390A (ja) | 置換イミダゾ[1,2−a]ピリジン誘導体、医薬組成物、及びβ−セクレターゼ阻害剤としての使用方法 | |
BG65106B1 (bg) | Заместени 2-арил-3-(хетероарил)-имидазо[1,2-а]пиримидини, лекарствени средства, които ги съдържат, използването им и метод за тяхното получаване | |
JP2005509592A (ja) | プロテインキナーゼインヒビターとしての5−(2−アミノピリミジン−4−イル)ベンズイソキサゾール | |
BG63769B1 (bg) | 1,2,4-тризаместени имидазоли, полезни като цитокини | |
MXPA03002294A (es) | Compuestos de pirazol utiles como inhibidores de proteina cinasa. | |
JP2004532234A (ja) | トリアゾール由来キナーゼインヒビターおよびその使用 | |
JP2008507534A (ja) | フラノピリジン誘導体および使用方法 | |
BG99879A (bg) | Инхибитори на нiv реверсивна транскриптаза | |
JP2013533318A (ja) | ヘテロアリールおよびその使用 | |
JP6629884B2 (ja) | 哺乳動物のチロシンキナーゼror1活性の阻害剤として有用な2−フェニル−3h−イミダゾ[4,5−b]ピリジン誘導体 | |
JP2010529129A (ja) | キナーゼ阻害剤化合物 | |
JP2013522364A (ja) | 置換イミダゾ[1,2−b]ピリダジン誘導体、医薬組成物、及びβ−セクレターゼ阻害剤としての使用の方法 | |
JP2018502141A (ja) | キナゾリン及びキノリン化合物、ならびにその使用 | |
US20050222186A1 (en) | Substituted diaminopyrimidines | |
US20080119515A1 (en) | Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis | |
CN111909133B (zh) | 作为布鲁诺酪氨酸激酶抑制剂的取代的1-氨基-1h-咪唑-5-甲酰胺 | |
TW202246243A (zh) | 胺基嘧啶化合物及其使用方法 | |
KR20170030550A (ko) | 퀴녹살린 화합물, 그것의 제조 방법 및 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |